Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection
Viruses · 2025
DOI: 10.3390/v17050675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Veronika Vaňová und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, Antibodies, Viral, COVID-19. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovak Research and Development Agency, SAS Programme for PhD students'grants Doktogrant, European Union's Horizon 2020 research and innovation program.
Abstract (Originalsprache)
Understanding the long-term dynamics of SARS-CoV-2 neutralizing antibodies is critical for evaluating vaccine-induced protection and informing booster strategies. In this longitudinal study, we analyzed 114 serum samples from 19 individuals across six time points over a three-year period following mRNA vaccination (Comirnaty) and natural SARS-CoV-2 infection. Using pseudotype-based neutralization assays against nine SARS-CoV-2 variants, including major Omicron subvariants (BA.1–BA.5, BQ.1.1, XBB), and anti-S1 IgG ELISA, we observed that antibody levels peaked after the third vaccine dose and remained relatively stable two years later. Neutralization titers rose markedly after the second and third doses, with the highest neutralization observed at two years post-booster. Strong correlations were found between anti-S1 IgG levels and mean neutralization titers for pre-Omicron variants (r = 0.79–0.93; p < 0.05), but only moderate for Omicron subvariants (r ≈ 0.50–0.64). Notably, hybrid immunity (vaccination plus infection) resulted in higher neutralization titers at the final time point compared to vaccine-only participants. The lowest neutralization was observed against XBB, underscoring the immune evasiveness of emerging variants. These findings support the importance of booster vaccination and highlight the added durability of hybrid immunity in long-term protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
- Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
- Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
ORCID-Profile: Veronika Vaňová, Jana Náhliková, Žofia Rádiková, Silvia Pastoreková, Boris Klempa
Förderung
- Slovak Research and Development Agency
- SAS Programme for PhD students'grants Doktogrant
- European Union's Horizon 2020 research and innovation program
- SAS Programme for PhD students’ grants Doktogrant
- European Union’s Horizon 2020 research and innovation program
Zitieren
APA
Vaňová, V., Náhliková, J., Ličková, M., Sláviková, M., Kajanová, I., Lukáčiková, Ľ., Sabo, M., Rádiková, Ž., Pastoreková, S., & Klempa, B. (2025). Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection. Viruses. https://doi.org/10.3390/v17050675
Vancouver
Vaňová V, Náhliková J, Ličková M, Sláviková M, Kajanová I, Lukáčiková Ľ, et al. Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection. Viruses. 2025. doi:10.3390/v17050675
BibTeX
@article{Vaov2025,
author = {Vaňová, Veronika and Náhliková, Jana and Ličková, Martina and Sláviková, Monika and Kajanová, Ivana and Lukáčiková, Ľubomíra and Sabo, Miroslav and Rádiková, Žofia and Pastoreková, Silvia and Klempa, Boris},
title = {Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17050675}
}
EUVIMED